Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Radiopharm Theranostics Limited ( (AU:RAD) ).
Radiopharm Theranostics Limited announced that it has reached 50% patient enrollment in its Phase 2b clinical trial for RAD 101 imaging in brain metastases. The early data from the trial shows significant tumor uptake and confirms metabolic activity in brain metastases, which could lead to a global Phase 3 trial if results are confirmed. This milestone strengthens the company’s confidence in completing enrollment and sharing top-line results in the first half of 2026, potentially enhancing its position in the oncology radiopharmaceuticals market.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited is a clinical-stage biopharmaceutical company specializing in the development of innovative oncology radiopharmaceuticals. The company focuses on areas of high unmet medical need and is listed on both the ASX and NASDAQ. Its pipeline includes a range of platform technologies for cancer diagnostics and therapeutics, including peptides, small molecules, and monoclonal antibodies, with clinical trials targeting various solid tumor cancers such as lung, breast, and brain metastases.
Average Trading Volume: 6,526,243
Technical Sentiment Signal: Sell
Current Market Cap: A$61.17M
Learn more about RAD stock on TipRanks’ Stock Analysis page.